- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03929419
"Effect of Central Insulin Administration on Whole-body Insulin Sensitivity in Women"
The human brain is an insulin sensitive organ. Brain insulin action modulates peripheral insulin sensitivity in young lean men. As a underlying mechanism, the investigators previously detected suppression of endogenous glucose production and stimulation of glucose disappearance to peripheral tissue in response to brain insulin delivery by nasal spray. Whether this holds true in young woman is unknown, since differences in brain insulin response between sexes have been reported. The investigators will address this question by combining the delivery of insulin to the brain as nasal spray with hyperinsulinemic euglycemic clamp experiments in natural cycling women.
In the planned randomized, placebo controlled cross-over study, female participants will undergo four hyperinsulinemic euglycemic experiments with tracer dilution, two in the first phase and two in the second phase of their menstrual cycle. On one of the study days per menstrual phase, subjects will receive intranasal insulin administration, on the other placebo spray. The protocol has been successfully applied previously in men. Based on the results of this trial, the investigators calculated a required sample size of N=10 for the planned study in women.
These experiments will help to better understand the role of brain insulin action in a broader sense. The results can be the basis for larger clinical trials that address the sex-specific impact of brain insulin resistance for glucose metabolism and diabetes risk.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
"Effect of central insulin administration on whole-body insulin sensitivity in women" The human brain is an insulin sensitive organ. Brain insulin action modulates peripheral insulin sensitivity in young lean men. As a underlying mechanism, the investigators previously detected suppression of endogenous glucose production and stimulation of glucose disappearance to peripheral tissue in response to brain insulin delivery by nasal spray. Whether this holds true in young woman is unknown, since differences in brain insulin response between sexes have been reported. The investigators will address this question by combining the delivery of insulin to the brain as nasal spray with hyperinsulinemic euglycemic clamp experiments in natural cycling women.
In the planned randomized, placebo controlled cross-over study, female participants will undergo four hyperinsulinemic euglycemic experiments with tracer dilution, two in the first phase and two in the second phase of their menstrual cycle. On one of the study days per menstrual phase, subjects will receive intranasal insulin administration, on the other placebo spray. The protocol has been successfully applied previously in men. Based on the results of this trial, the investigators calculated a required sample size of N=10 for the planned study in women.
These experiments will help to better understand the role of brain insulin action in a broader sense. The results can be the basis for larger clinical trials that address the sex-specific impact of brain insulin resistance for glucose metabolism and diabetes risk.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Tuebingen, Germany, 72076
- University of Tuebingen, Department of Internal Medicine IV
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- female volunteer adults
- HbA1c <6.0%
- Age between 18 and 30 years
- Standard routine laboratory
- No underlying diseases
- No medication
- No hormonal contraception
- Understanding of the explanations of the study and the instructions
Exclusion Criteria:
- Persons with limited temperature perception and / or increased temperature Sensitivity to warming of the body
- Cardiovascular disease, such as manifest coronary Heart disease, heart failure greater than NYHA 2, recent myocardial infarction
- People with a hearing disorder or increased sensitivity to loud Sounds
- persons with claustrophobia
- Minors or non-consenting subjects are also excluded
- Pregnancy or breastfeeding women
- Surgery less than 3 months ago
- Simultaneous participation in other interventional studies
- Acute illness or infection within the last 4 weeks
- Neurological and psychiatric disorders
- Subjects with hemoglobin Hb <12g / dl (at screening)
- Allergic diseases
- Individuals with a history of heparin-induced thrombocytopenia (HIT)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Insulin nasal spray
160 Units of human insulin as nasal spray
|
application of 160 units human insulin
|
Placebo Comparator: Placebo nasal spray
Nasal spray containing placebo solution
|
nasal spray containing placebo solution
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the peripheral insulin sensitivity
Time Frame: 60-90 minutes and 150-210 minutes during euglycemic clamp
|
Effect of nasal insulin versus placebo on peripheral insulin sensitivity assessed by euglycemic hyperinsulinemic clamp.
|
60-90 minutes and 150-210 minutes during euglycemic clamp
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation with autonomous nervous system activity
Time Frame: 70-80 minutes and 190-200 minutes during euglycemic clamp
|
Correlation of the change in peripheral insulin sensitivity by central insulin action with the simultaneous change of the autonomous nervous system (measured by heart rate variability).
|
70-80 minutes and 190-200 minutes during euglycemic clamp
|
Differential effects dependent on female sexual hormones
Time Frame: 60-90 minutes and 150-210 minutes during euglycemic clamp
|
Correlation of the change in peripheral insulin sensitivity by central insulin action dependent on the time point in menstrual cycle
|
60-90 minutes and 150-210 minutes during euglycemic clamp
|
Effect of menstrual cycle on insulin sensitivity before spray application
Time Frame: 60-90minutes
|
Will be measured by hyperinsulinemic euglycemic clamp
|
60-90minutes
|
Effect of menstrual cycle on brain insulin sensitivity
Time Frame: 60-90 minutes
|
Brain insulin sensitivity will be assessed by functional magnetic resonance imaging combined with intranasal insulin administration during the follicular and the luteal phase of the menstrual cycle
|
60-90 minutes
|
Effect of menstrual cycle on processing of food cues in the brain
Time Frame: 20 minutes
|
Processing of food cues in the brain will be assessed by functional magnetic resonance imaging during the follicular and the luteal phase of the menstrual cycle
|
20 minutes
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 568/2018BO1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Insulin Sensitivity
-
Paloma Almeda-ValdésCompleted
-
Ingredion IncorporatedUnknownFocus of the Study is Insulin SensitivityUnited States
-
University of Colorado, DenverRecruitingEndothelial Dysfunction | Vascular Stiffness | Insulin Sensitivity/Resistance | TransgenderismUnited States
-
University of Texas, El PasoCompletedInsulin Sensitivity/ResistanceUnited States
-
Rigshospitalet, DenmarkUnknownInsulin Sensitivity and Lipid Metabolism
-
Maastricht University Medical CenterCompletedVascular Function | Nitrate | Brain Insulin-sensitivityNetherlands
-
University of Alabama at BirminghamNot yet recruitingCardiovascular Diseases | Obesity | Insulin Sensitivity/Resistance | Metabolic Disease | Energy Expenditure | MetabolismUnited States
-
University of CopenhagenCompleted
-
Marjukka KolehmainenKuopio University HospitalCompleted
-
NeuroBo Pharmaceuticals Inc.CompletedInsulin Sensitivity
Clinical Trials on intranasal insulin
-
Michigan State UniversityCompletedExercise | InsulinUnited States
-
Wake Forest University Health SciencesCompleted
-
University Health Network, TorontoCompleted
-
Texas Tech University Health Sciences CenterCompletedHypogonadotropic HypogonadismUnited States
-
University of BirminghamQueen Elizabeth Hospital NHS Foundation TrustCompleted
-
Johns Hopkins UniversityTerminatedHIV Dementia | HIV-Associated Cognitive Motor ComplexUnited States
-
University Health Network, TorontoCompletedInsulin Resistance, DiabetesCanada
-
Centre for Addiction and Mental HealthRecruitingDepression | Major Depressive DisorderCanada
-
HealthPartners InstituteJuvenile Diabetes Research Foundation; International Diabetes Center at Park...TerminatedType1diabetesUnited States
-
Rutgers, The State University of New JerseyAlzheimer's AssociationRecruitingMetabolic Syndrome | Alzheimer Disease | Mild Cognitive ImpairmentIsrael